Nuvation Bio (NUVB)

• Market cap: $2.76B
• 1 day: -4.85%
• 5 days: -5.41%
• 1 month: 0.5%
• 3 months: 114.4%
• 6 months: 239.24%
• Year to date: -6.29%
• 1 year: 189.21%
• 5 years: -26.64%
• 10 years: -17.11%
• Sector: Healthcare
• Industry: Biotechnology

About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Employees: 291